 It has had promising results in a clinical trial for advanced soft tissue and bone sarcoma.Ridaforolimus is being co-developed by Merck and ARIAD Pharmaceuticals.On May 5, 2010, Ariad Pharmaceuticals and Merck & Company announced a clinical development and marketing agreement.